Pricing Log in Create free account

IMMURON (IMRN) vs MetaVia Inc. (MTVA)

IMMURON and MetaVia Inc. are both Biotechnology companies. IMMURON and MetaVia Inc. are of similar size ($7.2M and $6.9M). MetaVia Inc. has the higher net margin (0.00% vs −262.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 9 metrics below, IMMURON leads on 5 and MetaVia Inc. on 4.

Valuation

Metric IMRN MTVA Biotechnology median
P/E n/m n/m 10.60
P/S n/m n/m 9.40
P/B n/m 1.22 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.93 0.04 0.66
EV/Sales (3.47) n/m 9.02
Earnings yield (2.51%) (285.73%) (32.88%)
Free cash flow yield 0.00% (190.70%) (23.13%)

Profitability

Metric IMRN MTVA Biotechnology median
Gross margin 71.28% — 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin (262.71%) 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (175.68%) (51.96%)
Return on assets 0.00% (91.06%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric IMRN MTVA Biotechnology median
Revenue growth (TTM) (6.62%) — 6.76%
EPS growth (last fiscal year) 37.29% 81.23% 29.88%
Revenue growth, 5-year CAGR 116.96% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMRN MTVA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.26 2.06 4.97
Net debt to EBITDA 1.81 0.75 1.01

Dividend

Metric IMRN MTVA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric IMRN MTVA Biotechnology median
Market cap 6.86m 7.18m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack